Takeda Pharmaceutical Company Limited TAK
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.05B | -895.43M | 775.80M | 259.30M | 958.61M |
| Total Depreciation and Amortization | 4.29B | 4.52B | 4.73B | 4.72B | 4.76B |
| Total Amortization of Deferred Charges | 271.12M | 271.12M | 265.19M | 265.19M | 265.19M |
| Total Other Non-Cash Items | 2.40B | 1.80B | 2.49B | 2.27B | 1.48B |
| Change in Net Operating Assets | 353.39M | 1.26B | -320.93M | 516.29M | -108.88M |
| Cash from Operations | 6.26B | 6.95B | 7.94B | 8.03B | 7.36B |
| Capital Expenditure | -1.18B | -1.17B | -1.19B | -1.22B | -1.28B |
| Sale of Property, Plant, and Equipment | 7.32M | 44.65M | 44.52M | 44.47M | 44.67M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 91.89M | 229.02M | 297.70M | 285.42M | 319.28M |
| Other Investing Activities | -1.66B | -1.52B | -1.32B | -553.52M | -705.69M |
| Cash from Investing | -2.74B | -2.42B | -2.18B | -1.44B | -1.62B |
| Total Debt Issued | 402.51B | 586.06B | 553.55B | 593.55B | 727.87B |
| Total Debt Repaid | -412.74B | -584.98B | -730.36B | -1.23T | -1.47T |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -1.01B | -51.60B | -101.58B | -101.58B | -101.58B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.02B | -2.09B | -2.10B | -2.08B | -2.09B |
| Other Financing Activities | -134.29B | -134.39B | -129.88B | -135.99B | -127.54B |
| Cash from Financing | -2.96B | -3.31B | -4.80B | -7.85B | -8.51B |
| Foreign Exchange rate Adjustments | 283.15M | 226.40M | 155.74M | 160.13M | -211.61M |
| Miscellaneous Cash Flow Adjustments | -100.00 | -6.40K | 6.60K | 6.60K | 6.60K |
| Net Change in Cash | 852.32M | 1.45B | 1.12B | -1.10B | -2.99B |